Sanofi, Regeneron get boost in PCSK9 rivalry; AstraZeneca pulls Lynparza from CDF eval; Aetna hasn't decided on Gilead vs. AbbVie hep C meds;

> Sanofi ($SNY) and Regeneron ($REGN) got a boost against rival Amgen ($AMGN) as new study data show that the companies' PCSK9 cholesterol-lowering antibody alirocumab is effective when given once a month. Story

> AstraZeneca ($AZN) withdrew its cancer drug Lynparza from England's Cancer Drugs Fund (CDF) evaluation process, one day after the fund announced that it would cut its list of covered meds. Story

> Aetna CEO Mark Bertolini said the company has not yet decided whether to cover Gilead Sciences ($GILD) or AbbVie's ($ABBV) hepatitis C drug, but is "actively working" on reaching a decision. More

> U.K. cost watchdog NICE gave a thumbs-down to Dendreon's ($DNDN) prostate cancer drug Provenge for the second time this year. Article

> Israel's MediSafe raised $6 million in funding to support development of its mobile platform for drug adherence. More

And Finally... Want to look smarter? Study shows eye contact and eyeglasses work, but five-dollar words don't. Report


Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.